Sitravatinib Combination Therapy for Solid Cancers

Recruiting at 25 trial locations

Overseen By Mirati Therapeutics Study Locator Services

Age: 18+

Sex: Any

Trial Phase: Phase 2 & 3

Sponsor: Mirati Therapeutics Inc.

Must be taking: Sitravatinib

Disqualifiers: Other cancer, Life-threatening illness, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

55 Participants Needed

Trial Summary

What is the purpose of this trial?

A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies

Research Team

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Eligibility Criteria

This trial is for patients already benefiting from Sitravatinib alone or with other cancer drugs in a previous study, without severe side effects or another life-threatening illness. The doctor must believe continuing treatment is good for the patient.

Inclusion Criteria

You are currently taking sitravatinib alone or with other medications in another study sponsored by Mirati.

Currently tolerating the treatment regimen in the parent protocol

You are currently receiving treatment that is helping you, and your doctor thinks it's best to continue this treatment.

Exclusion Criteria

I may have another type of cancer besides the one being treated.

I do not have any severe illnesses that could affect my safety in the study.

Treatment Details

Interventions

• Sitravatinib

Trial Overview The study tests if Sitravatinib, on its own or combined with drugs like Ipilimumab, Nivolumab, Pembrolizumab, and Enfortumab Vedotin-Ejfv helps advanced solid tumors. It's for those who saw benefits in an earlier Mirati-sponsored trial.

Participant Groups

Group I: Phase 2/3: Open label extension of parent study Experimental Treatment 5 Interventions

The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.

Who Is Running the Clinical Trial?

Mirati Therapeutics Inc.

Lead Sponsor

Trials

73

Recruited

8,900+

Dr. Charles M. Baum

Mirati Therapeutics Inc.

Chief Executive Officer since 2023

MD, PhD

Dr. Joseph Leveque

Mirati Therapeutics Inc.

Chief Medical Officer since 2021

MD